Tag: opdualag market size

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Opdualag Market Forecast: What Value Will The Market Reach By 2030?

The historical growth observed can be linked to the rising occurrence of advanced melanoma diagnoses, the successful outcomes from immune checkpoint inhibitor treatments, regulatory clearances for combined immunotherapy approaches, increasing financial commitments to oncology research, and the proliferation of specialized oncology facilities.

Anticipated growth during the forecast period is primarily fueled by the expanding use of personalized cancer treatment approaches, the increasing adoption of biomarker-driven therapies, rising investments in immuno-oncology pipelines, broader label expansions across various cancer indications, and a growing demand for durable cancer response therapies. Major trends expected in the forecast period include the expanding adoption of dual-checkpoint immunotherapy, a growing focus on LAG-3 targeted cancer treatments, increasing utilization of combination oncology regimens, a rise in clinical trials for advanced melanoma therapies, and an enhanced emphasis on precision immuno-oncology.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=61635356&type=smp&name=Opdualag%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Opdualag Market Growth Momentum: What Factors Are Shaping Demand?

The rising occurrence of advanced melanoma is anticipated to fuel the expansion of the opdualag market in the future. Advanced melanoma signifies a phase where cancerous cells have metastasized from the skin to other regions of the body, including lymph nodes, organs, or remote tissues. This rise in advanced melanoma cases is primarily linked to greater sun exposure, genetic predispositions, and improved diagnostic screening. Opdualag works to counteract advanced melanoma by merging nivolumab and relatlimab, thereby enhancing the immune system’s response and providing a focused therapeutic option for metastatic instances. For example, reports from Cancer Research UK, an independent UK-based cancer charity, indicate that in July 2024, the annual number of new melanoma skin cancer diagnoses in the UK is expected to grow considerably, moving from about 20,800 cases during 2023-2025 to an estimated 26,500 cases by 2038-2040. Consequently, the growing frequency of advanced melanoma is propelling the expansion of the opdualag market.

Opdualag Market Driver: Impact Of Increasing Healthcare Spending On The Market Growth

Opdualag Market Segment Landscape And Growth Outlook

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Mismatched Repair Deficient Or Microsatellite Instability-High, Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Classical Hodgkin Lymphoma (cHL), Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

3) By End User: Hospitals, Oncology Clinics, Pharmaceutical Distributors

Opdualag Market Trends Redefining Industry Growth

Leading firms within the Opdualag market are concentrating on creating novel solutions, including sophisticated dual immunotherapy combination therapies, to address the increasing need for enhanced cancer treatments capable of improving tumor management and achieving better long-term patient results. This approach, known as dual immunotherapy, involves combining two agents that target the immune system to concurrently inhibit several immune checkpoints, thereby providing a more comprehensive and powerful anti-tumor reaction than conventional single-agent immunotherapies. An example of this is the acceptance received by Bristol Myers Squibb, a US-based biopharmaceutical company, from the Scottish Medicines Consortium (SMC) in July 2024 for the application of Opdualag (nivolumab-relatlimab) within NHS Scotland. This approval designates it as a first-line immunotherapy for advanced melanoma in adults and adolescents aged 12 and above. Being the first approved LAG-3 blocking antibody combination, Opdualag broadens the available treatment choices for qualified patients in Scotland, a region where melanoma, presently the UK’s fifth most common cancer, affects over 1,200 people annually. Considering that around 10% of UK cases are identified at advanced stages and linked to less favorable prognoses, this approval marks a strategically important move towards improving access to cutting-edge cancer treatments and fulfilling a crucial outstanding clinical requirement.

Opdualag Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the opdualag market are Bristol-Myers Squibb Company

View The Full Opdualag Market Report:

https://thebusinessresearchcompany.com/report/opdualag-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Opdualag Market Regional Analysis: Which Geography Leads On Revenue?

North America was the largest region in the opdualag market in 2025. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Opdualag Market Growth Potential: How Will Market Size Change Through 2030?

The expansion observed during the historical period was driven by a rising number of advanced melanoma diagnoses, the demonstrated effectiveness of immune checkpoint inhibitors in clinical settings, official approvals granted for combined immunotherapy regimens, heightened funding dedicated to oncology studies, and the proliferation of specialized cancer treatment centers.

The forecast period’s growth is driven by the wider implementation of personalized cancer treatment methods, a greater uptake of biomarker-based therapies, increased funding for immuno-oncology development programs, extended label approvals across various cancer types, and a heightened need for treatments offering lasting cancer responses. Key trends shaping the forecast period include the broader utilization of dual-checkpoint immunotherapy, an escalating interest in lag-3 directed cancer therapies, more frequent application of combination oncology protocols, a surge in clinical investigations for advanced melanoma solutions, and a stronger focus on precision immuno-oncology.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20324&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Opdualag Market Demand Drivers Creating New Revenue Opportunities

The rising number of advanced melanoma cases is anticipated to drive the opdualag market forward in the coming years. Advanced melanoma represents a stage where the cancer has extended beyond the skin into other areas of the body, including lymph nodes, organs, or distant tissues. This increase is largely influenced by greater sun exposure and genetic factors, along with improved screening methods that enhance detection. Opdualag works against advanced melanoma by combining nivolumab and relatlimab to strengthen the immune response, offering a specific treatment choice for metastatic patients. As an example, in July 2024, Cancer Research UK, an independent charity based in the UK, released reports indicating that the annual number of new melanoma skin cancer cases in the UK is expected to rise markedly, from about 20,800 cases during 2023-2025 to an estimated 26,500 cases by 2038-2040. Consequently, the growing incidence of advanced melanoma is fueling the expansion of the opdualag market.

Growing healthcare expenditure is projected to boost the opdualag market in the future. Healthcare spending refers to the overall money used for health services, supplies, and research, encompassing both public and private investments aimed at preserving and enhancing public well-being. This spending is influenced by factors such as aging populations, an increased need for medical care, technological progress, and the elevated costs of treatments and medications. Opdualag can help reduce healthcare costs by delivering an efficient therapy for advanced melanoma, which may lower long-term expenses through improved patient results. For instance, in December 2024, Health Affairs, a US-based health policy journal, reported that healthcare spending in the United States went up by 7.5 percent in 2023, compared to a 4.6 percent growth rate in 2022. Hence, rising healthcare spending is propelling the growth of the opdualag market.

Opdualag Market Segment Performance And Strategic Opportunities

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Mismatched Repair Deficient Or Microsatellite Instability-High, Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Classical Hodgkin Lymphoma (cHL), Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

3) By End User: Hospitals, Oncology Clinics, Pharmaceutical Distributors

Opdualag Market Trends Driving Strategic Industry Expansion

Key players in the Opdualag market are prioritizing the creation of cutting-edge solutions, including advanced dual immunotherapy combination regimens, to address the growing need for more effective cancer treatments that enhance tumor suppression and deliver improved long-term patient outcomes. By employing two immune-targeting agents that simultaneously inhibit different immune checkpoints, dual immunotherapy generates a wider and more powerful anti-tumor effect than what is typically achieved with single-agent immunotherapies. A notable example occurred in July 2024, when Bristol Myers Squibb, an American biopharmaceutical company, obtained approval from the Scottish Medicines Consortium (SMC) for Opdualag (nivolumab-relatlimab) to be administered as a first-line immunotherapy within NHS Scotland for advanced melanoma affecting adults and adolescents aged 12 and older. As the first LAG-3 blocking antibody combination to receive approval, Opdualag expands the range of therapeutic choices for eligible patients in Scotland, where melanoma—currently the fifth most prevalent cancer in the UK—affects more than 1,200 individuals annually. Given that roughly 10% of UK cases are diagnosed at advanced stages, often linked with worse prognoses, this authorization represents a strategically important advancement in broadening access to innovative cancer therapies and fulfilling a significant unmet medical need.

Opdualag Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the opdualag market are Bristol-Myers Squibb Company

Access The Complete Opdualag Market Report:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Opdualag Market Regional Analysis And Leading Geography

North America was the largest region in the opdualag market in 2025. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Opdualag Market During The Forecast Period?

The growth observed during the historic period stemmed from a rise in advanced melanoma cases and the proven clinical effectiveness of immune checkpoint inhibitors. Further contributing factors include the regulatory endorsements for combination immunotherapies, alongside increasing financial commitments towards oncology research, and the expanding network of specialty oncology clinics.

Growth during the projected period is anticipated due to the wider implementation of personalized cancer treatment approaches, the increasing acceptance of therapies guided by biomarkers, growing financial commitments to immuno-oncology research and development, broader regulatory approvals across various cancer types, and an escalating demand for treatments offering lasting cancer responses. Significant trends expected in this forecast period encompass the expanding integration of dual-checkpoint immunotherapy, a heightened focus on LAG-3 targeted cancer treatments, the increased utilization of combination oncology regimens, a rise in clinical trials for advanced melanoma therapies, and a strengthened emphasis on precision immuno-oncology.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20324&type=smp

Which Strategic Drivers Are Supporting The Opdualag Market Development?

The rising occurrence of advanced melanoma is anticipated to drive the expansion of the opdualag market in the future. This condition, advanced melanoma, signifies cancer that has disseminated from the skin to other bodily areas, including lymph nodes, organs, or distant tissues. Its prevalence is primarily influenced by heightened sun exposure, genetic predispositions, and enhanced detection methods via screening. Opdualag contributes to managing advanced melanoma by synergizing nivolumab and relatlimab to amplify the immune response, thereby providing a focused therapeutic option for metastatic instances. For example, reports from Cancer Research UK, an independent UK-based cancer charity, in July 2024, indicate a substantial expected rise in new melanoma skin cancer cases annually in the UK, predicted to climb from around 20,800 cases between 2023-2025 to roughly 26,500 cases by 2038-2040. Consequently, the growing occurrence of advanced melanoma is fueling the expansion of the opdualag market.

What Are The Core Segment Classifications In The Opdualag Market?

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Mismatched Repair Deficient Or Microsatellite Instability-High, Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Classical Hodgkin Lymphoma (cHL), Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

3) By End User: Hospitals, Oncology Clinics, Pharmaceutical Distributors

Which Trends Are Expected To Shape The Opdualag Market?

Leading companies in the Opdualag market are concentrating on creating inventive solutions, notably advanced dual immunotherapy combination treatments, to satisfy the increasing need for more effective cancer therapies that enhance tumor management and long-term patient results. Dual immunotherapy involves merging two agents targeting the immune system to simultaneously obstruct multiple immune checkpoints, delivering a more extensive and powerful anti-tumor effect compared to traditional single-agent immunotherapies. For instance, in July 2024, the US-based biopharmaceutical firm Bristol Myers Squibb obtained acceptance from the Scottish Medicines Consortium (SMC) for Opdualag (nivolumab-relatlimab), enabling its use within NHS Scotland as a primary immunotherapy for advanced melanoma in adults and adolescents aged 12 and above. As the inaugural approved LAG-3 blocking antibody combination, Opdualag broadens the available treatment options for qualifying patients in Scotland, where melanoma, currently the UK’s fifth most common cancer, impacts more than 1,200 individuals each year. Given that approximately 10% of UK cases are identified at advanced stages with less favorable prognoses, this approval marks a strategically crucial development in improving access to novel cancer treatments and addressing a vital unmet clinical requirement.

Which Companies Are Engaged In The Opdualag Market Environment?

Major companies operating in the opdualag market are Bristol-Myers Squibb Company

Access The Complete Opdualag Market Report:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report

Which Geographic Region Represents The Largest Opdualag Market Share?

North America was the largest region in the opdualag market in 2025. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Opdualag Market Between 2026 And 2030?

The historical growth can be linked to the rising occurrence of advanced melanoma cases, successful clinical outcomes with immune checkpoint inhibitors, the granting of regulatory approvals for combination immunotherapies, expanding investments in oncology research, and an increase in specialty oncology clinics.

The expansion anticipated in the forecast period can be attributed to the broader implementation of personalized cancer treatment approaches, the increasing acceptance of biomarker-driven therapies, elevated investments in immuno-oncology pipelines, wider label expansions across various cancer indications, and a growing need for therapies that provide durable cancer responses. Prominent trends for this period include the expanded adoption of dual-checkpoint immunotherapy, a heightened focus on LAG-3 targeted cancer treatments, an increased reliance on combination oncology regimens, a rise in clinical trials for advanced melanoma therapies, and a strengthened emphasis on precision immuno-oncology.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20324&type=smp

What Primary Drivers Are Shaping The Opdualag Market?

The rising occurrence of advanced melanoma is anticipated to drive the expansion of the opdualag market in the future. This condition, advanced melanoma, signifies cancer that has disseminated from the skin to other bodily areas, including lymph nodes, organs, or distant tissues. Its prevalence is primarily influenced by heightened sun exposure, genetic predispositions, and enhanced detection methods via screening. Opdualag contributes to managing advanced melanoma by synergizing nivolumab and relatlimab to amplify the immune response, thereby providing a focused therapeutic option for metastatic instances. For example, reports from Cancer Research UK, an independent UK-based cancer charity, in July 2024, indicate a substantial expected rise in new melanoma skin cancer cases annually in the UK, predicted to climb from around 20,800 cases between 2023-2025 to roughly 26,500 cases by 2038-2040. Consequently, the growing occurrence of advanced melanoma is fueling the expansion of the opdualag market.

How Is The Opdualag Market Categorized Across Its Segment Groups?

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Mismatched Repair Deficient Or Microsatellite Instability-High, Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Classical Hodgkin Lymphoma (cHL), Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

3) By End User: Hospitals, Oncology Clinics, Pharmaceutical Distributors

What Trends Are Affecting The Growth Of The Opdualag Market?

Leading companies in the Opdualag market are concentrating on developing creative solutions, such as sophisticated dual immunotherapy combination treatments, to address the increasing need for more potent cancer therapies that enhance tumor management and long-term clinical outcomes. Dual immunotherapy works by combining two immune-targeting agents to concurrently block multiple immune checkpoints, providing a broader and more powerful anti-tumor response compared to traditional single-agent immunotherapies. For instance, in July 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, obtained acceptance from the Scottish Medicines Consortium (SMC) for the use of Opdualag (nivolumab-relatlimab) within NHS Scotland. This is intended as a first-line immunotherapy for advanced melanoma in adults and adolescents aged 12 and above. As the first approved LAG-3 blocking antibody combination, Opdualag extends treatment possibilities for eligible patients in Scotland, where melanoma, currently the UK’s fifth most common cancer, affects over 1,200 individuals annually. Considering that approximately 10% of UK cases are diagnosed at advanced stages and linked to poorer outcomes, this approval signifies a strategically important step in improving access to innovative cancer therapies and fulfilling a critical unmet clinical need.

Which Firms Are Influencing Competition In The Opdualag Market?

Major companies operating in the opdualag market are Bristol-Myers Squibb Company

Get The Full Opdualag Market Report:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report

Which Region Represents The Largest Share Of The Opdualag Market?

North America was the largest region in the opdualag market in 2025. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Opdualag Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report

Browse Through More Reports Similar to the Global Opdualag Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Opc Server Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/opc-server-software-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Opdualag Market Over The 2026–2030 Period?

Historical growth stemmed from a rising incidence of advanced melanoma cases, the clinical effectiveness of immune checkpoint inhibitors, regulatory approvals granted for combination immunotherapies, increasing investments in oncology research, and the expansion of specialty oncology clinics.

The projected growth during the forecast period can be attributed to the broadening of personalized cancer treatment approaches, the increasing uptake of therapies guided by biomarkers, higher investments in immuno-oncology pipelines, wider label expansions across various cancer indications, and a growing demand for treatments that provide durable cancer responses.

Key trends anticipated in the forecast period encompass the expanding adoption of dual-checkpoint immunotherapy, a growing focus on LAG-3 targeted cancer treatments, the increasing use of combination oncology regimens, a rise in clinical trials for advanced melanoma therapies, and an enhanced emphasis on precision immuno-oncology.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20324&type=smp

What Drivers Are Expected To Influence The Opdualag Market During The Forecast Period?

The rising occurrence of advanced melanoma is anticipated to boost the expansion of the opdualag market in the future. This condition describes a point when cancer has progressed past the skin to affect other bodily areas, including lymph nodes, organs, or remote tissues. The prevalence of advanced melanoma primarily stems from heightened exposure to sunlight, genetic predispositions, and improved detection methods via screening. Opdualag aids in treating advanced melanoma by combining nivolumab and relatlimab, which works to strengthen the immune response and deliver a precise therapy for metastatic instances. For example, reports from Cancer Research UK, a UK-based independent cancer charity, indicated in July 2024 that the yearly number of new melanoma skin cancer cases in the UK is expected to grow considerably, from around 20,800 cases between 2023 and 2025 to an estimated 26,500 cases by 2038-2040. Consequently, the increasing incidence of advanced melanoma is fueling the expansion of the opdualag market.

How Is The Opdualag Market Segmented Across Key Categories?

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Mismatched Repair Deficient Or Microsatellite Instability-High, Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Classical Hodgkin Lymphoma (cHL), Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

3) By End User: Hospitals, Oncology Clinics, Pharmaceutical Distributors

Which Upcoming Trends Are Expected To Influence The Opdualag Market?

Key players within the Opdualag market are concentrating on creating novel solutions, including sophisticated dual immunotherapy combination therapies, to satisfy the growing need for more efficacious cancer treatments that enhance tumor management and extended clinical results. Dual immunotherapy involves the fusion of two immune-targeting agents to concurrently inhibit numerous immune checkpoints, thereby providing a more extensive and powerful anti-tumor reaction than conventional single-agent immunotherapies. As an illustration, in July 2024, Bristol Myers Squibb, a US-based biopharmaceutical firm, obtained approval from the Scottish Medicines Consortium (SMC) for Opdualag (nivolumab-relatlimab) for its application within NHS Scotland as a primary immunotherapy for advanced melanoma in adults and young people aged 12 and above. Being the inaugural approved LAG-3 blocking antibody combination, Opdualag broadens the range of therapeutic choices for suitable patients in Scotland, a region where melanoma, presently the UK’s fifth most prevalent cancer, affects more than 1,200 individuals each year. Given that approximately 10% of UK cases are diagnosed in advanced phases and linked with less favorable prognoses, this acceptance signifies a strategically crucial advancement in improving availability to cutting-edge cancer treatments and fulfilling a vital unaddressed clinical necessity.

Who Are The Dominant Players Shaping The Opdualag Market Landscape?

Major companies operating in the opdualag market are Bristol-Myers Squibb Company

Read the full opdualag market report here:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report

Which Region Is Forecast To Lead The Opdualag Market In Terms Of Market Size?

North America was the largest region in the opdualag market in 2025. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Opdualag Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20324&type=smp

Browse Through More Reports Similar to the Global Opdualag Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Opc Server Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/opc-server-software-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the opdualag market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Opdualag Market size between 2026 and 2035?

The expansion observed in the historical period was propelled by an escalating frequency of advanced melanoma diagnoses, the demonstrated clinical efficacy of immune checkpoint inhibitors, regulatory authorizations granted for combination immunotherapies, increased investments in oncology research, and the enlargement of specialized oncology clinics.

The anticipated growth during the forecast period is due to the broadening of individualized cancer treatment methods, the greater uptake of therapies guided by biomarkers, escalating investments in immuno-oncology drug development, wider approval of treatments for various cancer types, and the increasing need for long-lasting cancer responses from therapies. Key trends anticipated for the forecast period encompass the wider acceptance of dual-checkpoint immunotherapy, a heightened focus on cancer treatments targeting LAG-3, the rising implementation of combination oncology treatment plans, an increase in clinical trials for therapies aimed at advanced melanoma, and a greater emphasis on precise immuno-oncology approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20324&type=smp

Which Drivers Are Impacting Market Performance In The Opdualag Market?

The escalating occurrence of advanced melanoma is anticipated to drive the expansion of the opdualag market. Advanced melanoma signifies a stage where cancer has progressed beyond the skin to other regions of the body, such as lymph nodes, organs, or distant tissues. The prevalence of advanced melanoma is primarily influenced by increased sun exposure and genetic factors, alongside improvements in detection through screening. Opdualag aids in counteracting advanced melanoma by combining nivolumab and relatlimab to enhance the immune response, offering a targeted therapy for metastatic situations. For example, reports released by Cancer Research UK in July 2024 indicate that the yearly incidence of new melanoma skin cancer cases in the UK is projected to rise significantly, from approximately 20,800 cases in the 2023-2025 period to an estimated 26,500 cases by 2038-2040. Thus, the increasing incidence of advanced melanoma is a key factor propelling the growth of the opdualag market.

Which Segments Are Contributing To The Growth Of The Opdualag Market?

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Mismatched Repair Deficient Or Microsatellite Instability-High, Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Classical Hodgkin Lymphoma (cHL), Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

3) By End User: Hospitals, Oncology Clinics, Pharmaceutical Distributors

What Trends Are Reshaping The Dynamics Of The Opdualag Market?

Leading companies in the Opdualag market are concentrating on developing inventive solutions, such as sophisticated dual immunotherapy combination treatments, to satisfy the increasing demand for more potent cancer therapies that enhance tumor management and long-term clinical outcomes. Dual immunotherapy involves combining two immune-targeting agents to concurrently block multiple immune checkpoints, thereby offering a broader and more powerful anti-tumor response compared to conventional single-agent immunotherapies. For instance, in July 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, received acceptance from the Scottish Medicines Consortium (SMC) for Opdualag (nivolumab-relatlimab) for use within NHS Scotland as a first-line immunotherapy for advanced melanoma in adults and adolescents aged 12 and above. As the initial approved LAG-3 blocking antibody combination, Opdualag extends treatment options for eligible patients in Scotland, where melanoma, currently the UK’s fifth most common cancer, affects over 1,200 individuals annually. With approximately 10% of UK cases diagnosed at advanced stages and linked to less favorable outcomes, this approval represents a strategically important move in improving access to innovative cancer therapies and addressing a critical unfulfilled clinical need.

Who Are The Core Companies Influencing Trends In The Opdualag Market?

Major companies operating in the opdualag market are Bristol-Myers Squibb Company

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report

Which Regions Are Projected To Dominate The Opdualag Market In The Coming Years?

North America was the largest region in the opdualag market in 2025. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Opdualag Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20324&type=smp

Browse Through More Reports Similar to the Global Opdualag Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Opc Server Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/opc-server-software-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the opdualag market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Opdualag Market size between 2026 and 2035?

The expansion observed in the historical period was propelled by an escalating frequency of advanced melanoma diagnoses, the demonstrated clinical efficacy of immune checkpoint inhibitors, regulatory authorizations granted for combination immunotherapies, increased investments in oncology research, and the enlargement of specialized oncology clinics.

The anticipated growth during the forecast period is due to the broadening of individualized cancer treatment methods, the greater uptake of therapies guided by biomarkers, escalating investments in immuno-oncology drug development, wider approval of treatments for various cancer types, and the increasing need for long-lasting cancer responses from therapies. Key trends anticipated for the forecast period encompass the wider acceptance of dual-checkpoint immunotherapy, a heightened focus on cancer treatments targeting LAG-3, the rising implementation of combination oncology treatment plans, an increase in clinical trials for therapies aimed at advanced melanoma, and a greater emphasis on precise immuno-oncology approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20324&type=smp

Which Drivers Are Impacting Market Performance In The Opdualag Market?

The escalating occurrence of advanced melanoma is anticipated to drive the expansion of the opdualag market. Advanced melanoma signifies a stage where cancer has progressed beyond the skin to other regions of the body, such as lymph nodes, organs, or distant tissues. The prevalence of advanced melanoma is primarily influenced by increased sun exposure and genetic factors, alongside improvements in detection through screening. Opdualag aids in counteracting advanced melanoma by combining nivolumab and relatlimab to enhance the immune response, offering a targeted therapy for metastatic situations. For example, reports released by Cancer Research UK in July 2024 indicate that the yearly incidence of new melanoma skin cancer cases in the UK is projected to rise significantly, from approximately 20,800 cases in the 2023-2025 period to an estimated 26,500 cases by 2038-2040. Thus, the increasing incidence of advanced melanoma is a key factor propelling the growth of the opdualag market.

Which Segments Are Contributing To The Growth Of The Opdualag Market?

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Mismatched Repair Deficient Or Microsatellite Instability-High, Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Classical Hodgkin Lymphoma (cHL), Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

3) By End User: Hospitals, Oncology Clinics, Pharmaceutical Distributors

What Trends Are Reshaping The Dynamics Of The Opdualag Market?

Leading companies in the Opdualag market are concentrating on developing inventive solutions, such as sophisticated dual immunotherapy combination treatments, to satisfy the increasing demand for more potent cancer therapies that enhance tumor management and long-term clinical outcomes. Dual immunotherapy involves combining two immune-targeting agents to concurrently block multiple immune checkpoints, thereby offering a broader and more powerful anti-tumor response compared to conventional single-agent immunotherapies. For instance, in July 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, received acceptance from the Scottish Medicines Consortium (SMC) for Opdualag (nivolumab-relatlimab) for use within NHS Scotland as a first-line immunotherapy for advanced melanoma in adults and adolescents aged 12 and above. As the initial approved LAG-3 blocking antibody combination, Opdualag extends treatment options for eligible patients in Scotland, where melanoma, currently the UK’s fifth most common cancer, affects over 1,200 individuals annually. With approximately 10% of UK cases diagnosed at advanced stages and linked to less favorable outcomes, this approval represents a strategically important move in improving access to innovative cancer therapies and addressing a critical unfulfilled clinical need.

Who Are The Core Companies Influencing Trends In The Opdualag Market?

Major companies operating in the opdualag market are Bristol-Myers Squibb Company

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report

Which Regions Are Projected To Dominate The Opdualag Market In The Coming Years?

North America was the largest region in the opdualag market in 2025. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Opdualag Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20324&type=smp

Browse Through More Reports Similar to the Global Opdualag Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Opc Server Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/opc-server-software-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Opdualag Market Grown from 2024 to 2025?

In recent times, there has been a substantial expansion in the opdualag market size, showing an HCAGR of XX. The market is set to escalate from $XX million in 2024, reaching $XX million in 2025, with a compound annual growth rate (CAGR) shadowing XX%. This augmentation during the historical phase is credited to the surge in advanced melanoma cases, enhanced healthcare consciousness, improved cancer survival ratios, increased government backing and funds, and a rise in ultraviolet radiation exposure incidents.

What Growth Rate Is Anticipated for the Opdualag Market in the Coming Years?

Predictions indicate that the opdualag market will witness a forward compound annual growth rate (FCAGR) of XX% in the coming years. By 2029, its worth is anticipated to reach $XX million. The projected growth over the forecast period is credited to an escalated demand for better diagnostic solutions, heightening popularity of intralesional therapy, ongoing clinical research, regulatory approval of new treatments, an aging population, and a rise in melanoma instances. Important developments expected during this period include increased utilization of immunotherapy, integration of multiple therapies, customized cancer treatments, biosimilars development, and the use of digital tools in cancer treatment.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20324&type=smp

Who Are the Leading Companies in the Opdualag Market?

Major companies operating in the opdualag market are Bristol-Myers Squibb Company

What Are the Key Drivers of the Opdualag Market?

The growth of the opdualag market is anticipated to be driven by the rising occurrence of advanced melanoma. This is a stage of cancer that has spread beyond the skin and reached other areas of the body, such as lymph nodes, organs, or distant tissues. The primary factors causing an increase in advanced melanoma are more sun exposure and genetic elements, along with improved screening methods. Opdualag is useful in preventing advanced melanoma as it combines nivolumab and relatlimab to enhance immune response, providing a targeted remedy for metastatic instances. For example, as per Cancer Research UK, a UK-based autonomous cancer charity, the yearly incidence of new melanoma skin cancer occurrences in the UK is expected to dramatically escalate, going from roughly 20,800 cases in 2023-2025 to a projected 26,500 cases between 2038-2040. Consequently, the escalating occurrence of advanced melanoma is propelling the opdualag market’s expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20324&type=smp

What Are the Key Market Segments in the Opdualag Industry?

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC); Melanoma; Mismatched Repair Deficient Or Microsatellite Instability-High; Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Renal Cell Carcinoma (RCC); Classical Hodgkin Lymphoma (cHL); Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales; Online Pharmacies; Wholesale Distributors

3) By End User: Hospitals; Oncology Clinics; Pharmaceutical Distributors

What Are the Latest Trends in the Opdualag Market?

A principal trend in the opdualag market sector involves the creation of enhanced dual immunotherapy combination treatments, designed to increase the efficacy of cancer treatments and yield improved clinical results for patients. This type of treatment relies on two separate immune-targeting therapies working simultaneously to stimulate the body’s immune defense against cancer, engaging multiple immune checkpoints or pathways to better manage tumor growth. For example, in September 2022, the US-based biopharmaceutical enterprise Bristol Myers Squibb reported that Opdualag, which incorporates the PD-1 inhibitor nivolumab and the LAG-3-blocking antibody relatlimab, had received approval from the European Commission (EC). This treatment is specifically designed for adults and adolescents from 12 years upwards who have unresectable or metastatic melanoma characterized by low tumor cell PD-L1 expression (less than 1%). The decision to approve was based on the positive data obtained from the Phase 2/3 RELATIVITY-047 trial which showed that Opdualag-treated patients had a median progression-free survival duration of 10.1 months, markedly exceeding the 4.6 months observed with solely nivolumab treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report

What Are the Key Regional Markets in the Opdualag Industry?

North America was the largest region in the opdualag market in 2024. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20324

This Report Delivers Insight On:

1. How big is the opdualag market, and how is it changing globally?

2. Who are the major companies in the opdualag market, and how are they performing?

3. What are the key opportunities and risks in the opdualag market right now?

4. Which products or customer segments are growing the most in the opdualag market?

5. What factors are helping or slowing down the growth of the opdualag market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Are the Key Projections for the CAGR of the Opdualag Market Size From 2025 to 2034?

The size of the opdualag market has seen a HCAGR of XX in the past few years. Predicted growth from $XX million in 2024 to $XX million in 2025 indicates a compound annual growth rate (CAGR) of XX%. This surge during the historical period is owing to a surge in advanced melanoma incidents, amplified awareness about health care, improved survival rates for cancer patients, government backing and funding, and a rise in instances of exposure to ultraviolet radiation.

The size of the opdualag market is predicted to witness a XX% Future Compound Annual Growth Rate (FCAGR) in the ensuing years, reaching a substantial $XX million by 2029. This growth during the forecast period can be credited to various factors including the escalation in demand for enhanced diagnostic solutions, the growing fondness towards intralesional therapy, active clinical trials and newly obtained regulatory approvals that innovate new treatments, an increasing population of elderly individuals, and the rising occurrence of melanoma. Noteworthy trends of the forecast timeline are the integration of immunotherapy, the usage of combination therapies, the introduction of personalized cancer treatment, the breakthrough of biosimilars, and the inclusion of digital resources in handling cancer.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20324&type=smp

What Are the Core Market Drivers Propelling Growth in the Opdualag Industry?

The escalating number of advanced melanoma instances is anticipated to accelerate the expansion of the opdualag market in the future. Advanced melanoma being a stage where the malignancy has extended beyond the skin, affecting other body parts like the lymph nodes, organs, or tissues distant from the skin. Rising sun exposure and genetic factors, along with improved detection due to screening, are the primary drivers of the rise in advanced melanoma. By utilizing a combination of nivolumab and relatlimab, opdualag stimulates the immune response, providing a targeted solution for metastatic conditions. As an illustration, Cancer Research UK, an independent charity involved with cancer in the UK, reported in July 2024, that the annual incidence of newly diagnosed melanoma skin cancer cases in the UK is anticipated to exponentially grow, increasing from about 20,800 cases during 2023-2025 to a predicted 26,500 cases by 2038-2040. Hence, the advancing number of advanced melanoma cases is catalyzing the growth of the opdualag market.

How Is the Opdualag Market Segmented?

The opdualag market covered in this report is segmented –

1) By Clinical Indications: Non-Small Cell Lung Cancer (NSCLC); Melanoma; Mismatched Repair Deficient Or Microsatellite Instability-High; Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Renal Cell Carcinoma (RCC); Classical Hodgkin Lymphoma (cHL); Unrothelial Carcinoma (UC)

2) By Distribution Channel: Direct Sales; Online Pharmacies; Wholesale Distributors

3) By End User: Hospitals; Oncology Clinics; Pharmaceutical Distributors

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20324&type=smp

Which Regions Are Driving the Next Phase of the Opdualag Market Growth?

North America was the largest region in the opdualag market in 2024. The regions covered in the opdualag market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Opdualag Industry?

One significant trend observed in the opdualag market is the growth in the creation of advanced dual immunotherapy combination treatments, which aim to amplify the impact of cancer therapies and yield enhanced clinical results for patients. This kind of treatment involves the utilization of two different immune-targeting therapies that trigger the body’s immune counteraction to cancer by hitting multiple immune checkpoints or pathways for superior tumor control. For example, in September 2022, Bristol Myers Squibb, an American biopharmaceutical firm, revealed that the European Commission (EC) has given its approval for Opdualag, which comprises the PD-1 inhibitor nivolumab and the LAG-3-blocking antibody relatlimab. This treatment is particularly intended for adolescents and adults aged 12 years and above who suffer from inoperable or metastatic melanoma that displays low PD-L1 expression in tumor cells (less than 1%). The approval was grounded on data from the Phase 2/3 RELATIVITY-047 trial, which indicated that a median progression-free survival period of 10.1 months was seen in patients treated with Opdualag. This greatly exceeded the 4.6 months observed with just nivolumab.

View the full report here:

https://www.thebusinessresearchcompany.com/report/opdualag-global-market-report

How Is the Opdualag Market Defined and What Are Its Core Parameters?

Opdualag is a combination immunotherapy treatment that includes nivolumab (a PD-1 inhibitor) and relatlimab (a LAG-3 inhibitor), designed to enhance the body’s immune response against cancer cells. Its purpose is to treat advanced melanoma and other cancers by improving immune system activity, offering a potential alternative to traditional cancer therapies.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20324

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model